Related Experiment Video
Updated: May 1, 2026

Author Spotlight: Advancing Cellular and Protein Engineering to Control Biological Functions and Develop Novel Therapies
Published on: September 27, 2024
Multisystem vasculopathy in deficiency of adenosine deaminase 2
Tejas Muniraju1, Rajeswari Sankaralingam2, Nidhi Ramesh Prabhu1
1Clinical Immunology and Rheumatology, Sri Ramachandra Institute of Higher Education and Research, Chennai, Tamil Nadu, India.
None:
Deficiency of adenosine deaminase 2 (DADA2) is a rare monogenic autoinflammatory vasculopathy characterised by systemic vasculitis, immune dysregulation and haematological abnormalities. We report a man in his 30s who presented with recurrent ischaemic strokes, cytopenias, renal microaneurysms, cardiomyopathy and gastrointestinal involvement. He was initially diagnosed with polyarteritis nodosa and treated with conventional immunosuppression, with poor clinical response. Genetic testing confirmed DADA2, following which infliximab therapy was initiated, resulting in clinical stabilisation and improvement in inflammatory and haematological parameters, with stabilisation of cardiac function. This case highlights the importance of early genetic diagnosis and timely initiation of tumour necrosis factor inhibitor therapy to prevent irreversible organ damage.
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Diabetes Insipidus II: Pathophysiology
Cardiomyopathy IV: Restrictive Cardiomyopathy
Coronary Artery Disease II: Pathophysiology
Cardiomyopathy III: Hypertrophic Cardiomyopathy

